EGFR-mutant NSCLC poses a notable challenge in immuno-oncology; despite occasional PD-L1 expression, these tumors typically exhibit low TMB, limited CD8+ T cell infiltration, and an overall immunologically “cold” tumor microenvironment (184). Here, EGFR is linked to neoplasm.